Risks
4 risks
Risk Intelligence
Q4 seasonality and anti-infective dependency
View Risks →Alkem Laboratories Limited — Q3 FY24
Alkem reported a strong Q3 FY24 with 9% YoY revenue growth and 160bps EBITDA margin expansion to 21.3%, driven by lower API costs and favorable mix shift toward higher-margin ROW markets.
bullish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Alkem reported a strong Q3 FY24 with 9% YoY revenue growth and 160bps EBITDA margin expansion to 21.3%, driven by lower API costs and favorable mix shift toward higher-margin ROW markets. Domestic business outperformed IPM by 20bps, led by gastro, VMN, and antidiabetic portfolios. The US business saw single-digit price erosion, a significant improvement from prior double-digit declines. Management guided for full-year EBITDA margin of ~17%, citing Q4 seasonality, but sees this as sustainable with potential for 50-100bps annual improvement. Key risk: Q4 seasonality and anti-infective dependency could pressure near-term margins.
अल्केम ने वित्त वर्ष 2024 की तीसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कमाई पिछले साल की तुलना में 9% बढ़ी। मुनाफा बढ़ाने की क्षमता (EBITDA मार्जिन) 21.3% हो गई, जो पिछले साल से 1.6% ज्यादा है। इसकी वजह कच्चे माल की कम लागत और ज्यादा मुनाफे वाले बाजारों पर ध्यान देना है। भारत में कंपनी का कारोबार बाजार से बेहतर रहा, खासकर पेट, विटामिन और डायबिटीज की दवाओं में। अमेरिका में कीमतों में गिरावट पहले से कम हुई है। कंपनी का अनुमान है कि पूरे साल मुनाफा करीब 17% रहेगा, लेकिन चौथी तिमाही में कम हो सकता है। हालांकि, लंबे समय में इसमें हर साल 0.5-1% सुधार की उम्मीद है। मुख्य जोखिम: चौथी तिमाही में कारोबार कम हो सकता है और एंटी-इंफेक्टिव दवाओं पर निर्भरता से मुनाफा दबाव में आ सकता है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Domestic business growth vs IPM
+20bps
+20bps vs IPM
Domestic business outperformed the Indian pharmaceutical market by 20 basis points in Q3.
Chronic portfolio contribution
17%
flat
Chronic therapies now contribute 17% of domestic sales, with antidiabetic growing 16%+ vs market 5%.
Net cash position
₹3,500 Cr
+₹600 Cr QoQ
Company generated ~₹600 Cr cash in Q3, ending with net cash of ₹3,500 Cr as of Dec 31, 2023.
Enzene biosimilar revenue run-rate
₹200 Cr
breakeven expected this year
Biosimilar subsidiary Enzene expected to achieve breakeven this fiscal with ~₹200 Cr revenue.
What Changed vs Last Quarter
NEW
Annual margin improvement of 50-100bps
Management reiterated internal target of 50-100bps annual EBITDA margin improvement going forward.
NEW
Enzene biosimilar breakeven this year
Biosimilar subsidiary Enzene expected to achieve breakeven in FY24 with revenue run-rate of ~₹200 Cr.
NEW
US facility CapEx of ~₹250 Cr for Enzene
Company investing ~₹250 Cr in a US biosimilar CDMO facility, expected to be operational in 2-3 years.
UPDATED
Full-year EBITDA margin guidance of ~17%
Management expects FY24 EBITDA margin around 17%, with Q4 seasonally weaker but sustainable at that level.
DROPPED
FY24 gross margin guidance maintained at 59.5%
Despite Q2 gross margin of 61%, management maintains annual guidance of ~59.5% due to expected normalization of U.S. product mix.
DROPPED
U.S. business high single-digit dollar growth for FY24
Management expects full-year U.S. revenue growth in high single digits in dollar terms over FY23.
DROPPED
8-9 ANDA filings in FY24
R&D filings will be back-ended; targeting 8-9 ANDA filings for the full year, with focus on complex products.
NEW RISK
Q4 seasonality and anti-infective dependency
Q4 historically weak due to seasonality and high anti-infective exposure, which could pressure margins.
NEW RISK
US biosimilar facility execution risk
Analyst questioned rationale for US facility given past St. Louis closure and competitive biosimilar landscape; management acknowledged learnings but remains confident.
NEW RISK
Red Sea freight cost impact
Rising freight costs due to Red Sea disruptions could impact export margins; management sees manageable impact unless spike worsens.
NEW RISK
Tax rate normalization post-FY26
Tax holidays for Sikkim facility end in FY26, potentially raising effective tax rate from 10-12% to 20-25%.
RISK GONE
U.S. product mix sustainability
Q2 gross margin benefited from favorable U.S. product mix, which may not persist in coming quarters, potentially pressuring margins.
RISK GONE
Dabigatran supply chain challenges
Despite being one of two approved generics, supply chain issues persist due to FDA-dependent secondary API source; no near-term resolution.
RISK GONE
Pen G price uncertainty
Pen G prices remain elevated at $28-30 vs pre-COVID $8-10; any further increase or delayed normalization could hurt gross margins.
RISK GONE
Sluggish domestic acute business
India acute business underperformed due to delayed monsoons; recovery depends on seasonality and may not sustain.
Fast read
Guidance and risk preview
Management expects FY24 EBITDA margin around 17%, with Q4 seasonally weaker but sustainable at that level.
Q4 historically weak due to seasonality and high anti-infective exposure, which could pressure margins.
View Risks →